Goldman Sachs
SUPN icon

Goldman Sachs’s Supernus Pharmaceuticals SUPN Stock Holding History

Goldman Sachs’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-38,500
Closed -$1.91M – 6955
2025
Q4 		$1.91M Buy
+38,500
New +$1.87M ﹤0.01% 4633

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs's SUPN Position: Q1 2026 in Review

Goldman Sachs increased its Supernus Pharmaceuticals (SUPN) stake by 30% in Q1 2026, buying an estimated $9.99M and bringing the position to 856,487 shares worth $44.3M. The position accounts for 0.01% of the portfolio, ranked #1681.

Goldman Sachs first reported a position in SUPN in Q4 2013 and has held it in 49 quarters since. The position peaked at $55.6M in Q3 2025. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Goldman Sachs held 856,487 shares of Supernus Pharmaceuticals worth $44.3M as of Q1 2026.
  • Goldman Sachs bought 196,177 Supernus Pharmaceuticals shares in Q1 2026, an estimated $9.99M.
  • Supernus Pharmaceuticals made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #1681 holding.
  • Goldman Sachs first reported a position in Supernus Pharmaceuticals in Q4 2013 and has held it in 49 quarters since.
  • Goldman Sachs's Supernus Pharmaceuticals position peaked at $55.6M in Q3 2025.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.